Search results for "obesity drugs"

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts are calling for structured...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are increasingly recognized for benefits...
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs

Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs

As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop...
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone

Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone

South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1...
The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less

The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less

"First I’ll lose the weight, and then I’ll start exercising." It is a thought shared by almost anyone starting highly...
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use

GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use

A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
Resistance in the Genes: Why Popular Obesity Drugs Don’t Work for Everyone

Resistance in the Genes: Why Popular Obesity Drugs Don’t Work for Everyone

GLP-1 receptor agonists like Wegovy and Mounjaro have fundamentally reshaped the treatment of diabetes and obesity.
High Efficacy and Increased Convenience: The Three Obesity Drugs Awaiting FDA Approval

High Efficacy and Increased Convenience: The Three Obesity Drugs Awaiting FDA Approval

Since the World Health Organization recommended the use of obesity medications for adults last December, the market is...
The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care

The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care

GLP-1 receptor agonists (such as Wegovy and Ozempic), currently dominating the headlines as weight loss medications,...
Mild Cognitive Impairment Doesn’t Always Lead to Dementia—Early Diagnosis and Lifestyle Management Are Key

Mild Cognitive Impairment Doesn’t Always Lead to Dementia—Early Diagnosis and Lifestyle Management Are Key

Sept. 21 marks Dementia Overcoming Day, a designated observance created to raise public awareness about preventing and...